Microbiology and Immunology

You are here

Publications

Found 365 results

Author Title Type [ Year

]

Filters: First Letter Of Last Name is R [Clear All Filters]

2026

Hunt DM, Pisco JPedro, Rodgers A, de Chiara C, Zaveri A, Pacholarz KL, Evangelopoulos D, Garza-Garcia A, Ehrt S, Schnappinger D et al.. 2026. Activation of L-histidine biosynthesis as a new antibiotic strategy against Mycobacterium tuberculosis.. Nat Commun. 17(1)

Seshadri C, Flynn JAL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ et al.. 2026. Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.. Lancet Microbe. :101278.

Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al.. 2026. Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.

Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al.. 2026. Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.

Warrier T, Martinez-Hoyos M, de Francisco EPorras, Lenaerts AJ, Gruppo V, Robertson GT, Li K, Aubé J, Bonnet I, Jiang X et al.. 2026. Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.. ACS Infect Dis.

Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al.. 2026. Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.

Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al.. 2026. Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.

Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al.. 2026. Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.

Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al.. 2026. Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.

Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al.. 2026. Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.

Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al.. 2026. A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.

Courbon GM, Makarov V, Cole ST, Schnapinger D, Ehrt S, Rubinstein JL. 2026. Structural basis for EtfD-mediated coupling of β-oxidation and the respiratory chain in mycobacteria.. EMBO J. 45(8):2785-2807.

Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al.. 2026. Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.

Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al.. 2026. Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.

2025

Smith AA, Su H, Wallach J, Liu Y, Maiello P, H Borish J, Winchell C, Simonson AW, Lin PLing, Rodgers M et al.. 2025. A BCG kill switch strain protects against Mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity.. Nat Microbiol. 10(2):468-481.

Mishra S, Singh PRanjan, Hu X, Lopez-Quezada L, Jinich A, Jahn R, Geurts L, Shen N, DeJesus MA, Hartman T et al.. 2025. Candidate transmission survival genome of Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 122(10):e2425981122.

Davis SH, Mathieson M, Buchanan KI, Dawson A, Smith A, Cocco M, Tamaki FK, Post JM, Baragaña B, Jansen C et al.. 2025. Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.. J Med Chem. 68(15):16459-16482.

Davis SH, Mathieson M, Buchanan KI, Dawson A, Smith A, Cocco M, Tamaki FK, Post JM, Baragaña B, Jansen C et al.. 2025. Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.. J Med Chem. 68(15):16459-16482.

Palme PR, Grover S, Abdelaziz R, Mann L, Kany AM, Ouologuem L, Bartel K, Sonnenkalb L, Reiling N, Hirsch AKH et al.. 2025. Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase.. J Med Chem.

Palme PR, Grover S, Abdelaziz R, Mann L, Kany AM, Ouologuem L, Bartel K, Sonnenkalb L, Reiling N, Hirsch AKH et al.. 2025. Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase.. J Med Chem.

Palme PR, Grover S, Abdelaziz R, Mann L, Kany AM, Ouologuem L, Bartel K, Sonnenkalb L, Reiling N, Hirsch AKH et al.. 2025. Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase.. J Med Chem.

Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al.. 2025. Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.

Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al.. 2025. Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.

Dupnik KM, Dorvil N, Ward M, Rivera V, Apollon A, Dumont E, Sued O, Pape JW, Koenig SP. 2025. Histoplasma capsulatum Not Detected in People with HIV and Systemic Symptoms in Port-au-Prince, Haiti.. AIDS Res Hum Retroviruses.

Green SR, Harrison JR, Thompson S, Murugesan D, M Libardo DJ, Engelhart CA, Meshanni J, Fletcher D, Scullion P, Edwards D et al.. 2025. Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of Mycobacterium tuberculosis.. ACS Infect Dis. 11(3):715-726.